BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 35081484)

  • 1. Four cases of acquired hemophilia A following immunization with mRNA BNT162b2 SARS-CoV-2 vaccine.
    Leone MC; Canovi S; Pilia A; Casali A; Depietri L; Fasano T; Colla R; Ghirarduzzi A
    Thromb Res; 2022 Mar; 211():60-62. PubMed ID: 35081484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
    Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
    Front Immunol; 2022; 13():863554. PubMed ID: 35711445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.
    Haas EJ; Angulo FJ; McLaughlin JM; Anis E; Singer SR; Khan F; Brooks N; Smaja M; Mircus G; Pan K; Southern J; Swerdlow DL; Jodar L; Levy Y; Alroy-Preis S
    Lancet; 2021 May; 397(10287):1819-1829. PubMed ID: 33964222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolerability of COVID-19 Infection and Messenger RNA Vaccination Among Patients With a History of Kawasaki Disease.
    Beckley M; Olson AK; Portman MA
    JAMA Netw Open; 2022 Aug; 5(8):e2226236. PubMed ID: 35960521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Type 1 diabetes mellitus following SARS-CoV-2 mRNA vaccination.
    Aydoğan Bİ; Ünlütürk U; Cesur M
    Endocrine; 2022 Oct; 78(1):42-46. PubMed ID: 35809159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world settings at countrywide vaccination campaign in Saudi Arabia.
    Meo SA; Fahad Al-Jassir F; Al-Qahtani S; Albarrak R; Usmani AM; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Nov; 25(22):7185-7191. PubMed ID: 34859883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Case Report: Acquired Haemophilia A Following mRNA-1273 Booster Vaccination Against SARS-CoV-2 With Concurrent Diagnosis of Pleomorphic Dermal Sarcoma.
    Plüß M; Mitteldorf C; Szuszies CJ; Tampe B
    Front Immunol; 2022; 13():868133. PubMed ID: 35479071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective study.
    Wong CKH; Lau KTK; Xiong X; Au ICH; Lai FTT; Wan EYF; Chui CSL; Li X; Chan EWY; Gao L; Cheng FWT; Tang SCW; Wong ICK
    PLoS Med; 2022 Jun; 19(6):e1004018. PubMed ID: 35727759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study.
    Haas EJ; McLaughlin JM; Khan F; Angulo FJ; Anis E; Lipsitch M; Singer SR; Mircus G; Brooks N; Smaja M; Pan K; Southern J; Swerdlow DL; Jodar L; Levy Y; Alroy-Preis S
    Lancet Infect Dis; 2022 Mar; 22(3):357-366. PubMed ID: 34562375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Humoral immunity against SARS-CoV-2 in workers of social health care centers of Castilla y León after vaccination with the BNT162b2 mRNA vaccine from Pfizer/Biontech.].
    Casas Fischer R
    Rev Esp Salud Publica; 2021 Oct; 95():. PubMed ID: 34690347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A case of acquired hemophilia A and bullous pemphigoid following SARS-CoV-2 mRNA vaccination.
    Fu PA; Chen CW; Hsu YT; Wei KC; Lin PC; Chen TY
    J Formos Med Assoc; 2022 Sep; 121(9):1872-1876. PubMed ID: 35321820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection.
    Jones NK; Rivett L; Seaman S; Samworth RJ; Warne B; Workman C; Ferris M; Wright J; Quinnell N; Shaw A; ; Goodfellow IG; Lehner PJ; Howes R; Wright G; Matheson NJ; Weekes MP
    Elife; 2021 Apr; 10():. PubMed ID: 33830018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of Cerebral Venous Thrombosis Following SARS-CoV-2 Infection vs mRNA SARS-CoV-2 Vaccination in Singapore.
    Tu TM; Yi SJ; Koh JS; Saffari SE; Hoe RHM; Chen GJ; Chiew HJ; Tham CH; Seet CYH; Yong MH; Yong KP; Hui AC; Fan BE; Tan BY; Quek AML; Seet RCS; Yeo LLL; Tan K; Thirugnanam UN
    JAMA Netw Open; 2022 Mar; 5(3):e222940. PubMed ID: 35297971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore.
    Ng OT; Marimuthu K; Lim N; Lim ZQ; Thevasagayam NM; Koh V; Chiew CJ; Ma S; Koh M; Low PY; Tan SB; Ho J; Maurer-Stroh S; Lee VJM; Leo YS; Tan KB; Cook AR; Tan CC
    JAMA Netw Open; 2022 Aug; 5(8):e2228900. PubMed ID: 36018588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acquired Hemophilia A following Pfizer-BioNTech SARS CoV-2 mRNA vaccine, successfully treated with prednisolone and rituximab.
    Murali A; Wong P; Gilbar PJ; Mangos HM
    J Oncol Pharm Pract; 2022 Sep; 28(6):1450-1453. PubMed ID: 35088622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differing kinetics of anti-spike protein IgGs and neutralizing antibodies against SARS-CoV-2 after Comirnaty (BNT162b2) immunization.
    Bonura F; De Grazia S; Bonura C; Sanfilippo GL; Giammanco GM; Amodio E; Ferraro D
    J Appl Microbiol; 2022 May; 132(5):3987-3994. PubMed ID: 35083832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heterologous immunization with BNT162b2 followed by mRNA-1273 in dialysis patients: seroconversion and presence of neutralizing antibodies.
    Kohmer N; Rabenau HF; Ciesek S; Krämer BK; Göttmann U; Keller C; Rose D; Blume C; Thomas M; Lammert A; Lammert A
    Nephrol Dial Transplant; 2022 May; 37(6):1132-1139. PubMed ID: 35099023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Immune thrombocytopenia after BNT162b2 mRNA COVID-19 vaccination].
    Matsumura A; Katsuki K; Akimoto M; Sakuma T; Nakajima Y; Miyazaki T; Fujisawa S; Nakajima H
    Rinsho Ketsueki; 2021; 62(11):1639-1642. PubMed ID: 34866090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute asthma exacerbation due to the SARS-CoV-2 vaccine (Pfizer-BioNTech BNT162b2 messenger RNA COVID-19 vaccine [Comirnaty
    Ando M; Satonaga Y; Takaki R; Yabe M; Kan T; Omote E; Yamasaki T; Komiya K; Hiramatsu K
    Int J Infect Dis; 2022 Nov; 124():187-189. PubMed ID: 36122668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of hematological parameters and thrombocytopenia following Pfizer-BioNTech (BNT162b2) SARS-CoV-2 vaccination.
    Algaissi A; Alamer E; Jeraiby M; Alomaish A; Elrhima O; Qumayi S; Qasir NA; Areeshi H; Masmali A; Alhazmi A
    Saudi Med J; 2022 Jun; 43(6):567-571. PubMed ID: 35675927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.